MedTrace Logo

French Study on COgnitive Enhancement and Consumption of Psychoactive Substances Among Youth Students

NCT02954679 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30000

Last updated 2020-09-01

No results posted yet for this study

Summary

This descriptive and declarative study will help to find out consumption rates, all psychoactive substances taken together, among 18-25 year olds. More specifically, it will allow assessment of the extent of the cognitive enhancement phenomenon among students in France (including study of misuse of methylphenidate (MPH) and modafinil in improvement of cognitive performance).

Conditions

  • Psychoactive Substances Consumption
  • Substance-related Disorder
  • Off Label-use
  • Cognitive Enhancement

Interventions

OTHER

Online self-administrated and anonymous survey questionnaire

The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.

Sponsors & Collaborators

  • Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives - MILDECA

    collaborator UNKNOWN

  • Agence Nationale de sécurité du Médicament

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • DJEZZAR Samira · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-23
Primary Completion
2019-07-23
Completion
2019-07-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02954679 on ClinicalTrials.gov